Background Cancer is emerging as a major global health-care system challenge with a
growing burden worldwide. Due to the inconsistent cancer registry system in Saudi Arabia …

Background: Lymphomas account for approximately 10% of all cancer cases among the
Saudi population. Even when separated, Hodgkin lymphoma (HL) and non-Hodgkin …

Background: The current trends in lymphoma cases from Saudi Arabia and their long-term
survival are unknown. This study was conducted to evaluate the trends of lymphoma …

Abstract Objective Non-Hodgkin lymphomas (NHL) are a group of neoplastic
lymphoproliferative disorders, in which, its clinical spectrum, primary extra nodal variety …

The prognostic impact of CD20 expression and rituximab therapy in classical Hodgkin
lymphoma (cHL) is unclear. Among 310 patients, CD20 was expressed in 66 (22%) cases …

Hodgkin's lymphoma (HL) is a hematological malignancy characterized by a minority of
neoplastic cells outnumbered by tumor-associated macrophages (TAMs). The …

High-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT) can
salvage many patients with relapsed or refractory Hodgkin's lymphoma (HL). We are …

Introduction: Lymphoma, encompassing common non-Hodgkin lymphoma (NHL) and less
common Hodgkin lymphoma (HL), represents significant hematological malignancies …

In Hodgkin's lymphoma (HL), single nucleotide polymorphisms (SNPs) of specific DNA
repair genes have been identified to have an important role in the risk of HL. Consequently …

Background: The study aimed to determine the long-term response of rituximab on Non-
Hodgkin Lymphomas (NHL) patients. Methods: A retrospective cohort study was conducted …